Special Issue "Selected papers from 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020)"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery and Development".

Deadline for manuscript submissions: closed (31 October 2020).

Special Issue Editors

Prof. Yusnita Rifai
E-Mail
Guest Editor
Hasanuddin University, Indonesia
Interests: Drug Discovery, Including Exploring Natural Product Chemistry and Drug Synthesis
Prof. Dr. Nagendra Kumar Kaushik
E-Mail Website
Guest Editor
Department of Electrical and Biological Physics, /Plasma Bioscience Research Center /Applied Plasma Medicine Center, Kwangwoon University, 20 Kwangwoonro, Nowon-gu, Seoul 01897, South Korea
Interests: plasma medicine; biophysics; biomaterials; nanotechnology; nanomedicine
Special Issues and Collections in MDPI journals

Special Issue Information

Dear colleagues,

2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020) is the premier forum for the presentation of new advances and research results in the fields of theoretical, experimental, and applied Pharmacy, and Pharmaceutical Science and Biomedical Sciences. The special issue will bring together leading researchers, engineers and scientists in the domain of interest from around the world.

This Special Issue, “Special Issue of 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020)”, will mainly focus on pharmaceutics, nanotechnology; cosmetology; Drug Delivery Systems, clinical research and clinical trials and other related biomedical areas. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

ICPPS 2020 welcomes paper submission including abstract and full paper which is not published elsewhere. Topics of interest for submission include, but are not limited to:

  • Pharmaceutics
  • Drug Delivery Systems
  • Medicinal Chemistry, Pharmacology, Organic Chemistry
  • Nanotechnology
  • Drugs and Medical Devices: Regulatory Affairs
  • Pharmacy Business and Market
  • Radiopharmaceuticals
  • Nanotechnology in Pharmaceuticals
  • Novel Drug Delivery Systems
  • Bioavailability and Bioequivalence Studies
  • Clinical Research and Clinical Trials
  • Medical Biotechnology
  • Pharmaceutical Botany
  • Biopharmaceutics and Pharmacokinetics
  • Cosmetology
  • Radiopharmacy

A 10–20% discount is provided for publication in the Special Issue for all the attendees of the ICPPS 2020.

Prof. Yusnita Rifai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pharmaceutics
  • Radiopharmaceuticals
  • Nanotechnology
  • Cosmetology
  • Drug Delivery Systems
  • Biomedical Sciences

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Utility of Reactive Species Generation in Plasma Medicine for Neuronal Development
Biomedicines 2020, 8(9), 348; https://doi.org/10.3390/biomedicines8090348 - 12 Sep 2020
Viewed by 1115
Abstract
Reactive oxygen species (ROS) are critical signaling molecules for neuronal physiology that stimulate growth and development and play vital roles in several pathways when in a balanced state, but they cause neurodegeneration when unbalanced. As ROS levels above a certain threshold cause the [...] Read more.
Reactive oxygen species (ROS) are critical signaling molecules for neuronal physiology that stimulate growth and development and play vital roles in several pathways when in a balanced state, but they cause neurodegeneration when unbalanced. As ROS levels above a certain threshold cause the activation of the autophagy system, moderate levels of ROS can be used as treatment strategies. Currently, such treatments are used together with low-level laser or photodynamic therapies, photo-bio modulation, or infrared treatments, in different chronic diseases but not in the treatment of neurodegeneration. Recently, non-thermal plasma has been successfully used in biomedical applications and treatments, and beneficial effects such as differentiation, cell growth, and proliferation, stimulation of ROS based pathways have been observed. Besides the activation of a wide range of biological signaling pathways by generating ROS, plasma application can be an effective treatment in neuronal regeneration, as well as in neuronal diseases. In this review, we summarize the generation and role of ROS in neurons and provide critical insights into their potential benefits on neurons. We also discuss the underlying mechanisms of ROS on neuronal development. Regarding clinical applications, we focus on ROS-based neuronal growth and regeneration strategies and in the usage of non-thermal plasma in neuronal and CNS injury treatments. Full article
Show Figures

Figure 1

Open AccessReview
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
Biomedicines 2020, 8(9), 303; https://doi.org/10.3390/biomedicines8090303 - 23 Aug 2020
Viewed by 1540
Abstract
Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour [...] Read more.
Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals. Full article
Show Figures

Figure 1

Back to TopTop